Top Markets
#1 Seeker Seeker +134.41%
#2 AI XOVIA AI XOVIA +101.43%
#3 Helium Helium +70.37%
#4 MowCat MowCat +69.17%
#5 Pons Pons +40.95%
#6 UnifAI Network UnifAI Network +35.00%
#7 Zora Zora +29.90%
#8 Bounce Bounce +20.89%
#9 Zylo Ecosystem Zylo Ecosystem +20.85%
#10 TENDIES TENDIES +18.90%
Coin of the day
Seeker Seeker
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Jacobio Pharmaceuticals Group Co., Ltd. Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd.

1167
Classificação em ações #11796
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm... Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
Preço da ação
$0.84111496
Última sincronização: 2026-08-28
Valor de mercado
$657.90M
Variação (1 dia)
-0.75%
Variação (1 ano)
-19.13%
País
CN
Negociar Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Categoria

Healthcare
Lucros da Jacobio Pharmaceuticals Group Co., Ltd. (1167)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Jacobio Pharmaceuticals Group Co., Ltd., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Jacobio Pharmaceuticals Group Co., Ltd. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH